Zacks Investment Research upgraded shares of Trinity Biotech plc (NASDAQ:TRIB) from a sell rating to a hold rating in a research report sent to investors on Friday.

According to Zacks, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. “

Shares of Trinity Biotech plc (NASDAQ:TRIB) opened at 13.22 on Friday. The company’s 50 day moving average is $12.80 and its 200 day moving average is $11.62. Trinity Biotech plc has a one year low of $9.20 and a one year high of $14.52. The company has a market cap of $304.27 million, a P/E ratio of 56.26 and a beta of 0.92.

Trinity Biotech plc (NASDAQ:TRIB) last announced its earnings results on Thursday, July 21st. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.03. The firm earned $26.30 million during the quarter, compared to analysts’ expectations of $24.30 million. On average, equities analysts predict that Trinity Biotech plc will post $0.14 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the stock. Paradice Investment Management LLC raised its position in Trinity Biotech plc by 13.3% in the second quarter. Paradice Investment Management LLC now owns 1,626,496 shares of the company’s stock valued at $18,444,000 after buying an additional 190,772 shares during the last quarter. Janus Capital Management LLC raised its position in Trinity Biotech plc by 1.3% in the second quarter. Janus Capital Management LLC now owns 1,432,059 shares of the company’s stock valued at $16,240,000 after buying an additional 17,940 shares during the last quarter. Royce & Associates LP raised its position in Trinity Biotech plc by 13.7% in the first quarter. Royce & Associates LP now owns 799,098 shares of the company’s stock valued at $9,317,000 after buying an additional 96,500 shares during the last quarter. Bank of Montreal Can bought a new position in Trinity Biotech plc during the second quarter valued at $8,242,000. Finally, Emerald Acquisition Ltd. bought a new position in Trinity Biotech plc during the second quarter valued at $5,109,000.

Trinity Biotech plc Company Profile

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

5 Day Chart for NASDAQ:TRIB

Receive News & Ratings for Trinity Biotech plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech plc and related companies with Analyst Ratings Network's FREE daily email newsletter.